View company's website
1 known investors
Evercrisp develops machine learning-engineered miniproteins that enable targeted delivery of genetic medicine payloads to previously inaccessible tissues without relying on viral vectors or nanoparticles. The company serves patients with limited treatment options across diverse genetic diseases by making genome editing and oligonucleotide therapies safer and more effective.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
JD
Jennifer Doudna, Ph.D.
TK
Tanja Kortemme, Ph.D.
SL
Spiros Liras, Ph.D.